# Pizarra — PT-pseudo_0cdfb9410718 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_0cdfb9410718
Task: 1

Encounter: Urology - outpatient on 28 Jan 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 5.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.151 ng/mL²
  - PSA velocity: 1.62 ng/mL/yr
  - Prior PSA: 4.2 ng/mL
  - Prostate volume: 34.49 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.5618297 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 5.2 ng/mL. PI-RADS 4. PSAD 0.15. Prostate volume 34 mL. csPCa 0.56.

Vitals: weight 72 kg, height 169 cm, BMI 25.2, BP 143/64 mmHg, HR 68 bpm. Smoking: Ex-smoker (35 pack-yr, quit 2002).

Chief complaint: Persistent PSA elevation alongside previous prostate biopsy results prompts this clinical review.

History: A 68-year-old graphic designer entered the clinical pathway in late 2022 after a PSA of 2.2 ng/mL was identified. Married and currently residing alone while his spouse works elsewhere, he serves as the primary contact. Complete alcohol abstinence characterizes his habits, alongside a rigorous cycling routine of roughly 20 kilometres twice weekly. He carries a smoking history of 35 pack-years, having quit in 2002. Lower urinary tract symptoms remain negligible, reflected by an IPSS score of 1/35. Morning visitation suits his schedule due to public transit availability. Medical history lacks significant comorbidities or active medications. Recent interventions included physiotherapy for persistent lower back pain and a routine thyroid screening at an endocrine clinic. He explicitly denies unexplained weight loss, bone pain, or haematuria.

Physical examination: DRE reveals a symmetrically smooth prostate with normal dimensions and firmness, lacking any palpable nodules or asymmetry. Vital signs remain stable, and both cardiovascular and respiratory assessments fall within normal limits. General examination shows no peripheral lymphadenopathy or abdominal masses.

Patient info: graphic designer; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Cycling 2x/week, ~20 km; IPSS score: 1/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Physiotherapy — lower back, six sessions.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.62 +/- 0.13   (95% CI 0.35-0.88)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.13  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.96 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and patient agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or deferral, as the visible panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context of this patient, such as the PI-RADS 4 score, the rising PSA velocity (1.62 ng/mL/yr), and the prior positive biopsy status.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a 62% probability, which is highly susceptible to being wrong because the model did not account for the fact that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer?" to "is the existing cancer progressing or is this a new lesion?" The high aleatoric uncertainty (H=0.96) suggests the model is highly uncertain due to the conflicting data points (e.g., PI-RADS 4 vs. prior positive biopsy), meaning the suggestion is based on insufficient data to resolve this specific ambiguity.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
2. psa_trend - What is the serial PSA trend beyond the headline value?
3. previous_notes - What was the prior grade, surveillance pathway, and patient agreement?
4. laboratory panel - What are the full laboratory results to assess PSA density and other markers?

GUIDELINE ANCHOR
The guideline search indicates that the decision hinges on whether the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or deferral.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 4 lesion in the right anterior mid-gland, measuring 12 x 9 x 10 mm. No comparison with a previous MRI was explicitly stated in the report prose.
get_psa_trend
PSA trend: Aug 2022: 3.0 ng/mL, Nov 2023: 2.5 ng/mL, Jan 2025: 5.2 ng/mL. The trend shows a significant rise from 2.5 ng/mL in Nov 2023 to 5.2 ng/mL in Jan 2025.
get_previous_notes
Previous notes: Prior biopsy was performed, showing PSA levels advanced to 4.2 ng/mL by June 2024. The patient was documented as having persistent biochemical elevation and earlier histological findings.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents did not raise a specific question requiring this panel (e.g., regarding free-PSA or renal function before an invasive procedure).

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA trend shows a significant rise from 2.5 ng/mL (Nov 2023) to 5.2 ng/mL (Jan 2025).
- The current mpMRI shows a PI-RADS 4 lesion (12 x 9 x 10 mm) in the right anterior mid-gland.
- Previous notes confirm a prior positive biopsy and documented PSA progression to 4.2 ng/mL.

AGAINST sampling this patient now:
- The MRI report does not explicitly compare the current lesion size/zone against an earlier study.

WHERE THIS LEANS
The evidence strongly suggests progression given the rising PSA trend and the presence of a PI-RADS 4 lesion, which aligns with the statistical prior suggesting biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence strongly leans towards biopsy due to the rising PSA trend and the presence of a PI-RADS 4 lesion, despite the guideline criterion being inconclusive based on the panel alone. The missing laboratory results are noted but do not prevent a decision based on the current evidence.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision leans toward biopsy because the retrieved evidence showed a significant PSA trend from 2.5 ng/mL to 5.2 ng/mL and the presence of a PI-RADS 4 lesion. Although the guideline criterion was inconclusive, the statistical prior suggested biopsy, and the retrieved notes confirmed prior progression to 4.2 ng/mL. Since no retrieved document explicitly stated a prior grade or lesion stability, proceeding with sampling is justified to determine the progression of the known cancer.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
